Tevogen TVGN 深 滬
等待開盤 09-08 09:30:00 美东时间
7.34
+0.170
+2.37%
華盛通- 最 高7.34
- 今 開7.1235
- 成交量 1961股
- 最 低 6.935
- 昨 收 7.17
- 總市值 4779.47万
- 52周最高 43.66
- 市盈率 靜 --
- 換手率 0.03%
- 52周最低 3.6364
- 委 比 81.82%
- 總股本 651.15万
- 歷史最高 1054.50
- 量 比 0.47
- 振 幅 5.65%
- 歷史最低 6.935
- 每 手 1
- 風險率 11.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tevogen Bio becomes Tevogen Inc.
Tevogen Bio Holdings Inc. (TVGN) announced that it will operate under the name Tevogen Inc., following approval by its board of directors. The name change reflects Tevogen's ongoing evolution into a h...
07-29 21:12
Tevogen To Operate Under Tevogen Inc. Name, Effective July 30
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it will operate under the name Tevogen Inc., following approval by its Board of Directors. The name change reflects Tevogen's ongoing evolution into a healthcare enterprise where science, technology, and patient c...
07-29 20:03
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
Tevogen Bio Holdings Inc. has changed its name to Tevogen Inc., reflecting its evolution into a healthcare enterprise focused on integrating science, technology, and patient care. The name change will take effect on July 30, 2026, with no changes to its stock ticker symbols "TVGN" and "TVGNW." CEO Ryan Saadi emphasized the company's mission to create an integrated healthcare model to reduce medication costs and expand patient access.
07-29 12:00
Tevogen Bio Announces 2026 Annual Meeting of Stockholders
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) announced its 2026 Annual Meeting of Stockholders will be held virtually on August 24, 2026. Stockholders of record as of July 23, 2026, are entitled to vote. Proposals under Rule 14a-8 must be submitted by July 23, 2026, and comply with SEC rules. Additional proposals or nominations must follow Delaware law and the Company’s Bylaws. Tevogen focuses on improving the affordability and accessibility of life-...
07-14 02:15
Tevogen Creates Healthcare Services Initiative Led By VP Of Strategic Initiatives William Keane On Interim Basis
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced the formation of its healthcare services initiative, a strategic business area intended to support the Company's evolution into a broader,
06-10 03:32
Tevogen Announces Formation of a Healthcare Services Initiative
Tevogen announced the formation of its healthcare services initiative, led by William Keane as interim head, to evaluate potential acquisitions of a Management Services Organization (MSO) and a Contract Research Organization (CRO). These acquisitions aim to generate approximately $100 million in annual revenue and support the company's mission to improve healthcare affordability and access. The initiative complements Tevogen's existing biotechnol...
06-09 19:30
Tevogen Bio shares are trading higher after the company announced continued progress across its strategic acquisition initiatives.
Tevogen Bio shares are trading higher after the company announced continued pro...
05-29 02:24
Tevogen Bio Holdings shares are trading higher after the company announced it signed a non-binding Letter of Intent to evaluate a potential transaction with a Management Services Organization.
Tevogen Bio Holdings shares are trading higher after the company announced it s...
05-22 00:39
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization
Tevogen Bio Holdings Inc. has signed a non-binding Letter of Intent to evaluate a potential acquisition of a Management Services Organization (MSO). This transaction could enhance the company's healthcare infrastructure and support its growth into a revenue-generating enterprise combining Tevogen Bio (biotechnology), Tevogen.AI (technology), and a potential healthcare services arm. CEO Ryan Saadi, MD, MPH, expects the deal, along with other initi...
05-21 16:15
Letter to Shareholders from CEO Dr. Ryan Saadi
Tevogen CEO Dr. Ryan Saadi updates shareholders on the company's progress since its 2024 public listing, highlighting a 51% decline in operational losses from 2024 to 2025 and a 48% improvement in Q1 2026. The company advanced initiatives like Tevogen.AI and expanded its cell therapy pipeline while maintaining disciplined capital allocation. Potential revenue-generating acquisitions are under evaluation, and long-term incentives are being aligned...
05-18 16:15
